Harmony Biosciences Holdings, Inc. · NASDAQ:HRMY
Harmony Biosciences — Q4 2022 Earnings Presentation
11 slides from Harmony Biosciences's earnings presentation, Feb 21, 2023
Slide 1: Q4 & Full Year 2022 Financial and Business Update
Q4 & Full Year 2022 Financial and Business Update February 21, 2023
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes forward‐looking statements within the meaning of the Private Securities Reform Act of 1995. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding Harmony Biosciences Hol
Slide 3: Our Three-Pillar Growth Strategy
Our Three-Pillar Growth Strategy Optimize WAKIX® Expand Clinical Utility of Acquire Performance Pitolisant New Assets DESIGNED TO SUPPORT LONG TERM SUSTAINABLE GROWTH 3
Slide 4: WAKIX Net Revenue Performance
WAKIX® Net Revenue Performance CONFIDENT IN WAKIX BECOMING A POTENTIAL >$1B+ FRANCHISE VIA NARCOLEPSY AND ADDITIONAL INDICATIONS WAKIX QUARTERLY NET REVENUE ($M) WAKIX ANNUAL NET REVENUE ($M) 43% $437.9 41% $128.4 $117.2 $107.0 $305.4 $91.2 $85.3 $80.7 $73.8 $56.3 $59.7 $45.6 $38.0 $19.8 $6.0 Q4 19
Slide 5: Driving Growth Through Strong Commercialization of WAKIX
Driving Growth Through Strong Commercialization of WAKIX® Q4 2022 Performance >80% ~4,900 U.S. Covered Lives With Average # of Formulary Access Patients on WAKIX Continued Growth in Depth & Breadth of Prescriber Base ~85% In-Person Access to HCPs 5
Slide 6: Development Pipeline
Development Pipeline Regulatory Marketed Product / Indication Pre-IND Phase 1 Phase 2 Phase 3 Filing1 Milestone Product WAKIX® EDS in Narcolepsy (Adults) Cataplexy in Narcolepsy (Adults) Pitolisant Positive CHMP Pediatric Narcolepsy2 Opinion 1Q2023 Idiopathic Hypersomnia Trial initiated (IH) 2Q2022
Slide 7: Financial Highlights
Financial Highlights (In millions, USD) Three Months Ended Year Ended December 31, 2022 December 31, 2022 41% 43% $437.9 $128.3 $305.4 Net Product $91.2 Revenues Q4 2021 Q4 2022 FY 2021 FY 2022 100% 103% $183.5 Non-GAAP Adjusted $61.9 $91.7 $30.4 Net Income(1) Q4 2021 Q4 2022 FY 2021 FY 2022 $316.0
Slide 8: Financial Summary
Financial Summary (In millions, USD) Three Months Ended Year Ended December 31, % Change December 31, % Change Totals may not foot due to rounding 2022 2021 2022 2021 Net Product Revenues $128.3 $91.2 41% $437.9 $305.4 43% Cost of Product Sold 26.9 17.8 51% 83.5 55.5 50% Total Operating Expenses $53
Slide 9: GAAP vs NON-GAAP Reconciliation
GAAP vs NON-GAAP Reconciliation (In millions, USD) Three Months Ended Year Ended December 31, December 31, Totals may not foot due to rounding 2022 2021 2022 2021 GAAP net income $48.5 $22.7 $181.5 $34.6 Non-cash interest expense(1) 0.4 0.4 1.7 2.2 Depreciation 0.1 0.1 0.4 0.4 Amortization(2) 6.0 4.
Slide 10: Harmony Continues To Be A Growth Story
Harmony Continues To Be A Growth Story Strong Commercial Poised to Extend Pitolisant Performance & Future Value Proposition Beyond Growth of WAKIX in Narcolepsy with IH, PWS Narcolepsy & DM New Development Talented Team & Programs to Expand Solid Balance Sheet Portfolio, Treatment Positioned for Nex
Slide 11: Thank You
H3 HARMONY BIOSCIENCES Thank You
Harmony Biosciences Holdings — Q4 2022 Earnings Presentation on 6ix